Exhibit 99.3

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS

On March 1, 2013, Wright completed the acquisition of BioMimetic, a public company specializing in the development and commercialization of innovative products to promote the healing of musculoskeletal injuries and diseases, including therapies for orthopedic, sports medicine and spine applications. The transaction combines BioMimetic’s biologics platform and pipeline with Wright’s established sales force and product portfolio, to further accelerate growth opportunities in Wright’s Extremities business.

The following unaudited pro forma condensed combined financial statements give effect to the merger of Wright and BioMimetic in a transaction to be accounted for under the acquisition method of accounting in accordance with Financial Accounting Standards Board (FASB) Accounting Standard Codification (ASC) Section 805, Business Combinations, (ASC 805), with Wright treated as the legal and accounting acquirer.

The unaudited pro forma condensed combined balance sheet is based on the individual historical consolidated balance sheets of Wright and BioMimetic as of December 31, 2012, and has been prepared to reflect the merger of Wright and BioMimetic as of December 31, 2012. The unaudited pro forma condensed combined statement of operations is based on the individual historical consolidated statements of operations of Wright and BioMimetic and combines the results of operations of Wright and BioMimetic for the year ended December 31, 2012, giving effect to the merger as if it occurred on January 1, 2012. The historical financial information has been adjusted in the unaudited pro forma condensed combined financial statements to give effect to pro forma events that are directly attributable, factually supportable, and with respect to the unaudited pro forma condensed combined statement of operations, expected to have a continuing impact on the combined results. In addition, the unaudited pro forma condensed combined financial statements do not reflect any of the synergies or cost reductions that may result from the merger and do not include any restructuring costs or other one-time charges that may be incurred in connection with integrating the operations of Wright and BioMimetic. These unaudited pro forma condensed combined financial statements are for informational purposes only. They do not purport to indicate the results that would have actually been obtained had the merger been completed on the assumed date or for the periods presented, or which may be realized in the future. To produce the pro forma financial information, Wright adjusted BioMimetic’s assets and liabilities to their estimated fair values. The purchase price allocation is considered preliminary and is subject to revision when the deferred tax adjustments and the valuations of inventory, property, plant and equipment, and intangible assets are finalized upon receipt of the final valuation report for those assets from a third party valuation expert.

The unaudited pro forma condensed combined financial statements should be read in conjunction with:

1

WRIGHT MEDICAL GROUP INC.

UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET

As of December 31, 2012

(In thousands)

See accompanying Notes to the Unaudited Pro Forma Condensed Combined Financial Information

2

WRIGHT MEDICAL GROUP INC.

UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS

Year Ended December 31, 2012

(In thousands, except per share data)

See accompanying Notes to the Unaudited Pro Forma Condensed Combined Financial Information

3

NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS

1. DESCRIPTION OF TRANSACTION AND BASIS OF PRESENTATION

The unaudited pro forma condensed combined financial statements were prepared in accordance with US GAAP and pursuant to the rules and regulations of the Securities and Exchange Commission Regulation S-X, and present the pro forma financial position and results of operations of the consolidated companies based upon the historical information after giving effect to the merger and adjustments described in these footnotes. The unaudited pro forma condensed combined balance sheet is presented as if the merger had occurred on December 31, 2012 and the unaudited pro forma condensed combined statement of operations for the year ended December 31, 2012 is presented as if the merger had occurred on January 1, 2012.

On November 19, 2012, BioMimetic entered into a merger agreement with Wright, under which Wright will continue as the surviving entity. The acquisition was completed on March 1, 2013. The transaction was accounted for under the acquisition method of accounting in accordance with accounting principles generally accepted in the United States of America, with Wright treated as the accounting acquirer. Under the acquisition method of accounting, all of BioMimetic’s assets acquired and liabilities assumed in the transaction were recorded by Wright at their acquisition date fair values while transaction costs associated with the transaction were expensed as incurred. Under the terms of the Merger Agreement, each share of BioMimetic common stock was canceled and converted into the right to receive (1) $1.50 in cash (2) 0.2482 of a share of Wright common stock; and (3) one tradable Contingent Value Right (CVR). Each CVR entitles its holder to receive additional cash payments of up to $6.50 per share, which are payable upon receipt of FDA approval of Augment^® Bone Graft and upon achieving certain revenue milestones.

In addition, each holder of a BioMimetic stock option, whether such stock option was vested or unvested, was permitted to elect for all or any portion of such stock option to be exercised, whether in full or on a net basis, by agreeing (if exercised on a net basis) to exchange in the merger the shares of BioMimetic stock subject to such stock option being exercised, and, in connection with such exchange, relinquish a portion of the merger consideration otherwise payable pursuant to such shares. On the completion of the merger, any such stock option that was not exercised was assumed by Wright and converted into a stock option at a conversion rate of .522106 to acquire a number of shares of Wright common stock (rounded to the nearest whole share).

2. PRELIMINARY CONSIDERATION TRANSFERRED

The merger has been accounted for using the acquisition method of accounting in accordance with ASC 805, which requires, among other things, that the assets acquired and liabilities assumed be recognized at their fair values, with any excess of the purchase price over the estimated fair values of the identifiable net assets acquired recorded as goodwill. In addition, ASC 805 establishes that the common stock issued to effect the merger be measured at the closing date of the merger at the then-current market price.

The fair value of consideration transferred is as follows (in thousands):

4

The fair value assigned to the CVRs and the associated liability related to payments under the contingent value rights agreement of $70.5 million is based upon the CVRs’ market opening price of $2.50 per CVR as of March 4, 2013, the first day of trading of the CVRs, and the quantity of CVRs issued. The fair value of the CVRs was offset by the value of the CVR component of merger consideration that would have been received by option holders of 0.2 million BioMimetic stock options. This value was tendered along with the stock options to cover $1.4 million of the total employee portion of the statutory withholding tax.

The fair value of the CVRs and the associated liability related to payments under the CVR agreement will be remeasured at the end of each reporting period based on the closing trading price on the last business day of the period and the number of CVRs outstanding as of that date. Changes in fair value will be recognized in results of operations.

For purposes of calculating the consideration transferred, the fair value based measure of the BioMimetic vested options was determined on a grant-by-grant basis using the Black-Scholes option pricing model with the following assumptions: (i) the closing market price of BioMimetic common stock of $9.49 on February 28, 2013; (ii) an expected remaining life considering the original expected life for the options, the remaining service period and the contractual life of the option as of March 1, 2013; (iii) volatility based on a blend of the historical stock price volatility of common stock over the most recent period equivalent to the expected life of the options; and (iv) the risk-free interest rate based on published U.S. Treasury yields for notes with comparable terms as the expected life of the options. The fair value measurement of the Wright replacement options was completed using the same assumptions except the closing market price of Wright common stock of $23.83 on March 1, 2013 was used instead of the BioMimetic common stock closing price.

5

3. PRELIMINARY FAIR VALUE OF NET ASSETS ASSUMED

The following is a summary of the preliminary estimated fair values of the net assets acquired (in thousands):

The purchase price allocation is considered preliminary and is subject to revision when the deferred tax adjustments and the valuations of inventory, property, plant and equipment, and intangible assets are finalized upon receipt of the final valuation report for those assets from a third party valuation expert.

The goodwill is attributable to the workforce of the acquired business and strategic opportunities that arose from the acquisition of BioMimetic. The goodwill is not expected to be deductible for tax purposes.

The contractual value of accounts receivables approximates fair value. Prepaid and other current assets include $3.5 million, which represents the fair value of a contingent gain associated with disputed provisions of a license agreement with Luitpold.

4. PRO FORMA ADJUSTMENTS

These amounts have not been included in the unaudited pro forma condensed combined statement of operations as they are non-recurring.

6

ASC 805 requires that the incremental fair value of replacement awards attributed to precombination service be recognized immediately. As such, Wright recognized a non-recurring compensation expense of $8.8 million as of the date of the merger. The $8.8 million is comprised of $2.2 million for the incremental fair value of replacement awards attributed to precombination service and $6.6 million for the acceleration of vesting of previously unvested BioMimetic awards exercised in connection with the acquisition.

ASC 805 requires that the fair value of replacement awards attributed to postcombination service be recognized over the remaining service period. As such, the Company will recognize compensation expense of $0.7 million as adjustments to the unaudited pro forma condensed combined statement of operations for the year ended December 31, 2012. This amount represents the additional compensation expense that will be recognized related to unvested replacement awards for employees, executive officers, and members of the boards of directors.

BioMimetic estimates that it will incur merger expenses of approximately $4.6 million in the transaction, of which no expenses have been incurred as of December 31, 2012.

The unpaid merger expenses are reflected in the unaudited pro forma condensed combined balance sheet as of December 31, 2012 as an accrued liability and a charge to retained earnings of $8.5 million. The $0.2 million of equity issuance costs have been reflected in Wright’s historical balance sheet as of December 31, 2012 as a reduction to additional paid-in capital. Additionally, $0.6 million of severance costs associated with the merger are reflected as an accrued liability and a charge to retained earnings. Because they will not have a continuing impact, the unpaid merger expenses and severance costs are not reflected in the unaudited pro forma condensed combined statement of operations.

7

The estimated fair value attributed to in-process research and development, or IPR&D, intangible assets represents an estimate of the fair value of purchased in-process technology for BioMimetic’s research programs that, have not reached technological feasibility and have no alternative future use. Only those research programs that had advanced to a stage of development where management believed reasonable net future cash flow forecasts could be prepared and a reasonable possibility of technical success existed were included in the estimated fair value. The estimated fair value of the IPR&D programs was determined based on estimates of expected future net cash flows. These expected future net cash flows included estimates for revenue and associated costs for the IPR&D programs based on: (i) relevant industry factors; (ii) current and expected trends in the product development life cycle; (iii) the completion of future clinical trials; (iv) the ability to obtain regulatory approval; and (v) the ability to manufacture and commercialize the products. The future net cash flows which reflect the different stages of development of each program are then present valued utilizing an estimate of the appropriate discount rate which is consistent with the uncertainties of the cash flows utilized. For purposes of preparing the unaudited pro forma condensed combined financial statements, Wright used publicly available information, market participant assumptions, BioMimetic’s existing cost and development assumptions, expected synergies and other cost savings that a market participant would be expected to realize as a result of the merger.

IPR&D is recorded as an indefinite-lived intangible asset until completion or abandonment of the associated research and development projects. Accordingly, no amortization expense is reflected in the pro forma adjustments. Wright will periodically evaluate these indefinite-life intangible assets. If a project is completed, the carrying value of the related intangible asset will be amortized over the remaining estimated life of the asset beginning in the period in which the project is completed. If a project becomes impaired or is abandoned, the carrying value of the related intangible asset will be written down to its fair value and an impairment charge will be taken in the period in which the impairment occurs. These intangible assets will be tested for impairment on an annual basis, or earlier if impairment indicators are present.

The estimated fair value attributed to acquired technology intangible assets represents an estimate of the fair value of the licensing fees related to an exclusive sublicense agreement with Luitpold. BioMimetic has licensed to Luitpold the rights to the exclusive worldwide marketing, distribution and sales of GEM 21S, BioMimetic’s first periodontal product. The estimated fair value attributed to the trademarks intangible asset represents an estimate of the fair value of the Augment trademarks. Augment is the commercial name of BioMimetic’s bone regeneration orthopedic product.

The estimated fair value of the acquired technology and trademarks was determined based on estimates of expected future cash flows using the relief from royalty method, discounted at a rate, consistent with the uncertainties of the cash flows utilized. For purposes of preparing the unaudited pro forma condensed combined financial statements, Wright used publicly available information, market participant assumptions, BioMimetic’s existing cost and development assumptions, expected synergies and other cost savings that a market participant would be expected to realize as a result of the merger and certain other high-level assumptions. Amortization expense will be recorded on a straight-line basis over the expected life of the acquired technology, 14 years, which approximates expected future cash flows. The trademarks have an indefinite life. The carrying value of the acquired technology and trademarks asset will be periodically reviewed to determine if the facts and circumstances suggest that a potential impairment may have occurred. Impairment charges, if any, will be recorded in the period in which the impairment occurs.

The non-compete agreement was valued using the “with or without” method. The “with or without” method measures the value of an asset as the difference between two scenarios. One scenario measures the value of a business “with” the asset. The other scenario measures the value “without” the asset. The method treats the difference between the two scenarios (with certain valuation adjustments) as the value of the asset. The key assumptions used in valuing the covenant not to compete agreements were the likelihood of competition absent an agreement of 20% and a discount rate of 13%. The useful life of the non-compete agreement is 2 years, which approximates the remaining life of the agreement.

8

Shares utilized in the calculation of pro forma basic and diluted net loss per share are as follows:

Other potentially dilutive securities consisting of stock options totaling 3.6 million for the year ended December 31, 2012, were excluded from the per share calculations above, because of their anti-dilutive effect.

9